Immune Pharmaceuticals Inc (NASDAQ:IMNP) has earned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $6.38 for the company and are forecasting that the company will post ($0.16) EPS for the current quarter, according to Zacks. Zacks has also given Immune Pharmaceuticals an industry rank of 75 out of 265 based on the ratings given to its competitors.
Immune Pharmaceuticals (NASDAQ:IMNP) traded up 6.1483% during midday trading on Tuesday, reaching $0.6198. 84,651 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $0.78 and its 200 day moving average is $1.30. The stock’s market cap is $18.77 million. Immune Pharmaceuticals has a 1-year low of $0.56 and a 1-year high of $2.28.
Immune Pharmaceuticals (NASDAQ:IMNP) last issued its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.17. Equities analysts anticipate that Immune Pharmaceuticals will post ($0.63) earnings per share for the current fiscal year.
A number of brokerages recently issued reports on IMNP. FBR & Co. restated an “outperform” rating on shares of Immune Pharmaceuticals in a report on Friday, October 30th. Roth Capital began coverage on shares of Immune Pharmaceuticals in a research note on Thursday, October 8th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Chardan Capital lifted their price target on shares of Immune Pharmaceuticals from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Tuesday, October 13th.
In other Immune Pharmaceuticals news, Director Daniel Kazado acquired 150,000 shares of the company’s stock in a transaction that occurred on Monday, December 7th. The stock was acquired at an average price of $0.78 per share, for a total transaction of $117,000.00. Following the acquisition, the director now directly owns 240,623 shares in the company, valued at $187,685.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Gedeon Teper acquired 18,400 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The stock was acquired at an average price of $1.36 per share, with a total value of $25,024.00. Following the acquisition, the chief executive officer now owns 4,557,905 shares in the company, valued at $6,198,750.80. The disclosure for this purchase can be found here.
Immune Pharmaceuticals Inc. is a United States-based clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics, including monoclonal antibodies, nano-therapeutics and antibody drug conjugates, for the treatment of inflammatory diseases and cancer. Its pipeline includes, Bertilimumab, which is a clinical-stage human antibody, targeting eotaxin-1, which is involved in a number of immune mediated diseases; NanomAbs, which is a technology platform that allows the targeted delivery of chemotherapeutics into cancer cells, and AmiKet, which is a topical neuropathic pain drug candidate. The Company’s oncology pipeline includes Crolibulin, which is a small molecule vascular disrupting agent and apoptosis inducer for the intended treatment of patients with solid tumors, and Azixa, which is a vascular disruptive agent in development for the treatment of primary brain cancers and metastatic tumors with brain involvement.
Immune Pharmaceuticals Inc. (IMNPQ) Stock Research Links
Always remember do your own research and lock profits when you have it, just my personal trading opinion.
